Literature DB >> 29457869

Assessment of the spectrum of hepatic encephalopathy: A multicenter study.

Bradley Reuter1, Kara Walter2, Julien Bissonnette3, Michael D Leise4, Jennifer Lai5, Puneeta Tandon6, Patrick S Kamath4, Scott W Biggins2, Christopher F Rose3, James B Wade1, Jasmohan S Bajaj1.   

Abstract

Hepatic encephalopathy (HE) is a major cause of morbidity in cirrhosis. However, its severity assessment is often subjective, which needs to be studied systematically. The aim was to determine how accurately trainee and nontrainee practitioners grade and manage HE patients throughout its severity. We performed a survey study using standardized simulated patient videos at 4 US and 3 Canadian centers. Participants were trainees (gastroenterology/hepatology fellows) and nontrainees (faculty, nurse practitioners, physician assistants). We determined the accuracy of HE severity identification and management options between grades <2 or ≥2 HE and trainees/nontrainees. In total, 108 respondents (62 trainees, 46 nontrainees) were included. For patients with grades <2 versus ≥2 HE, a higher percentage of respondents were better at correctly diagnosing grades ≥2 compared with grades <2 (91% versus 64%; P < 0.001). Specialized cognitive testing was checked significantly more often in grades <2, whereas more aggressive investigation for precipitating factors was ordered in HE grades >2. Serum ammonia levels were ordered in almost a third of grade ≥2 patients. For trainees and nontrainees, HE grades were identified similarly between groups. Trainees were less likely to order serum ammonia and low-protein diets, more likely to order rifaximin, and more likely to perform a more thorough workup for precipitating factors compared with nontrainee respondents. There was excellent concordance in the classification of grade ≥2 HE between nontrainees versus trainees, but lower grades showed discordance. Important differences were seen regarding blood ammonia, specialized testing, and nutritional management between trainees and nontrainees. These results have important implications at the patient level, interpreting multicenter clinical trials, and in the education of practitioners. Liver Transplantation 24 587-594 2018 AASLD.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29457869      PMCID: PMC5912984          DOI: 10.1002/lt.25032

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  19 in total

Review 1.  Characteristics of minimal hepatic encephalopathy.

Authors:  Piero Amodio; Sara Montagnese; Angelo Gatta; Marsha Y Morgan
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

2.  Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.

Authors:  Hendrik Vilstrup; Piero Amodio; Jasmohan Bajaj; Juan Cordoba; Peter Ferenci; Kevin D Mullen; Karin Weissenborn; Philip Wong
Journal:  Hepatology       Date:  2014-07-08       Impact factor: 17.425

3.  The animal naming test: An easy tool for the assessment of hepatic encephalopathy.

Authors:  Francesca Campagna; Sara Montagnese; Lorenzo Ridola; Marco Senzolo; Sami Schiff; Michele De Rui; Chiara Pasquale; Silvia Nardelli; Ilaria Pentassuglio; Carlo Merkel; Paolo Angeli; Oliviero Riggio; Piero Amodio
Journal:  Hepatology       Date:  2017-05-27       Impact factor: 17.425

4.  The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis.

Authors:  Jasmohan S Bajaj; K Rajender Reddy; Puneeta Tandon; Florence Wong; Patrick S Kamath; Guadalupe Garcia-Tsao; Benedict Maliakkal; Scott W Biggins; Paul J Thuluvath; Michael B Fallon; Ram M Subramanian; Hugo Vargas; Leroy R Thacker; Jacqueline G O'Leary
Journal:  Hepatology       Date:  2016-02-19       Impact factor: 17.425

5.  Low likelihood of intracranial hemorrhage in patients with cirrhosis and altered mental status.

Authors:  Lucas M Donovan; Whitney L Kress; Luke C Strnad; Ammar Sarwar; Vilas Patwardhan; Gail Piatkowski; Elliot B Tapper; Nezam H Afdhal
Journal:  Clin Gastroenterol Hepatol       Date:  2014-06-04       Impact factor: 11.382

Review 6.  Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement.

Authors:  J S Bajaj; J Cordoba; K D Mullen; P Amodio; D L Shawcross; R F Butterworth; M Y Morgan
Journal:  Aliment Pharmacol Ther       Date:  2011-02-09       Impact factor: 8.171

7.  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Authors:  Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

8.  Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients.

Authors:  J S Bajaj; A J Sanyal; D Bell; H Gilles; D M Heuman
Journal:  Aliment Pharmacol Ther       Date:  2010-02-05       Impact factor: 8.171

9.  A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis.

Authors:  Ganesh Pantham; Anthony Post; Deepak Venkat; Douglas Einstadter; Kevin D Mullen
Journal:  Dig Dis Sci       Date:  2017-05-30       Impact factor: 3.199

10.  Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis.

Authors:  Tarek I Hassanein; Flemming Tofteng; Robert S Brown; Brendan McGuire; Patrick Lynch; Ravindra Mehta; Fin S Larsen; Jeff Gornbein; Jan Stange; Andres T Blei
Journal:  Hepatology       Date:  2007-12       Impact factor: 17.425

View more
  9 in total

Review 1.  Hepatic encephalopathy.

Authors:  Dieter Häussinger; Radha K Dhiman; Vicente Felipo; Boris Görg; Rajiv Jalan; Gerald Kircheis; Manuela Merli; Sara Montagnese; Manuel Romero-Gomez; Alfons Schnitzler; Simon D Taylor-Robinson; Hendrik Vilstrup
Journal:  Nat Rev Dis Primers       Date:  2022-06-23       Impact factor: 65.038

Review 2.  Diabetes mellitus - risk factor and potential future target for hepatic encephalopathy in patients with liver cirrhosis?

Authors:  Simon Johannes Gairing; Eva Maria Schleicher; Christian Labenz
Journal:  Metab Brain Dis       Date:  2022-08-24       Impact factor: 3.655

Review 3.  Serum Ammonia in Cirrhosis: Clinical Impact of Hyperammonemia, Utility of Testing, and National Testing Trends.

Authors:  Sasha Deutsch-Link; Andrew M Moon; Yue Jiang; A Sidney Barritt; Elliot B Tapper
Journal:  Clin Ther       Date:  2022-02-04       Impact factor: 3.637

4.  Predicting Overt Hepatic Encephalopathy for the Population With Cirrhosis.

Authors:  Elliot B Tapper
Journal:  Hepatology       Date:  2019-05-10       Impact factor: 17.425

5.  Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multicenter Study.

Authors:  Jennifer C Lai; Robert S Rahimi; Elizabeth C Verna; Matthew R Kappus; Michael A Dunn; Mara McAdams-DeMarco; Christine E Haugen; Michael L Volk; Andres Duarte-Rojo; Daniel R Ganger; Jacqueline G O'Leary; Jennifer L Dodge; Daniela Ladner; Dorry L Segev
Journal:  Gastroenterology       Date:  2019-01-19       Impact factor: 22.682

Review 6.  Hyperammonemia in Hepatic Encephalopathy.

Authors:  A R Jayakumar; Michael D Norenberg
Journal:  J Clin Exp Hepatol       Date:  2018-06-20

7.  Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis.

Authors:  Elliot B Tapper; James B Henderson; Neehar D Parikh; George N Ioannou; Anna S Lok
Journal:  Hepatol Commun       Date:  2019-09-06

8.  Speech patterns and enunciation for encephalopathy determination-A prospective study of hepatic encephalopathy.

Authors:  Andrew M Moon; Hannah P Kim; Sarah Cook; Renee T Blanchard; Katarina L Haley; Adam Jacks; Jennifer S Shafer; Michael W Fried
Journal:  Hepatol Commun       Date:  2022-07-21

9.  The autophagic marker p62 highlights Alzheimer type II astrocytes in metabolic/hepatic encephalopathy.

Authors:  Ellen Gelpi; Jasmin Rahimi; Sigrid Klotz; Susanne Schmid; Gerda Ricken; Sara Forcen-Vega; Herbert Budka; Gabor G Kovacs
Journal:  Neuropathology       Date:  2020-06-02       Impact factor: 1.906

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.